

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BALAS

Atty. Ref.: LB-5424-2

Appl. No. 09/739,089

Filed: December 15, 2000

For: METHOD AND SYSTEM FOR CHARACTERIZATION OF TISSUE LESIONS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 3.73 (b)

Forth Photonics Limited, a corporation states that it is:

1. ☒ the assignee of the entire right, title, and interest;

OR

2. ☐ an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is _____ % in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the Constantinos Balas (inventor), Demetrios Pelecoudas and The Foundation of Research and Technology-Hellas of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

☒ A Power of Attorney to prosecute applications before the USPTO is attached.

The undersigned has been authorized to act on behalf of the assignee in respect to this application/patent.

November 10, 2009

Date

703-816-4894

Telephone number

Leonidas Boutsikaris

Typed or printed name

/Leonidas Boutsikaris/

Signature

Reg. No.

61,377

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number:

23117

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:



The address associated with Customer Number:

23117

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone			Email


Assignee Name and Address:

Forth Photonics Ltd.
 Caprini House, 163-173 Praed Street
 London W21RH, United Kingdom

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	August 3, 2009
Name	CONSTANTIN BALAS	Telephone	+302106412860
Title	CTO		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)**Electronic Patent Assignment System****Confirmation Receipt**

Your assignment has been received by the USPTO.
The coversheet of the assignment is displayed below:

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Constantinos BALAS</td><td>08/14/2002</td></tr><tr><td>Demetrios PELECOUDAS</td><td>08/14/2002</td></tr><tr><td>The Foundation of Research and Technology Hellas</td><td>08/14/2002</td></tr></tbody></table>	Name	Execution Date	Constantinos BALAS	08/14/2002	Demetrios PELECOUDAS	08/14/2002	The Foundation of Research and Technology Hellas	08/14/2002			
Name	Execution Date										
Constantinos BALAS	08/14/2002										
Demetrios PELECOUDAS	08/14/2002										
The Foundation of Research and Technology Hellas	08/14/2002										
RECEIVING PARTY DATA											
<table border="1"><tr><td>Name:</td><td>FORTH PHOTONICS LIMITED</td></tr><tr><td>Street Address:</td><td>1 Mitchell Lane</td></tr><tr><td>City:</td><td>Bristol</td></tr><tr><td>State/Country:</td><td>UNITED KINGDOM</td></tr><tr><td>Postal Code:</td><td>BS1 6BU</td></tr></table>	Name:	FORTH PHOTONICS LIMITED	Street Address:	1 Mitchell Lane	City:	Bristol	State/Country:	UNITED KINGDOM	Postal Code:	BS1 6BU	
Name:	FORTH PHOTONICS LIMITED										
Street Address:	1 Mitchell Lane										
City:	Bristol										
State/Country:	UNITED KINGDOM										
Postal Code:	BS1 6BU										
PROPERTY NUMBERS Total: 1											
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>09739089</td></tr></tbody></table>	Property Type	Number	Application Number:	09739089							
Property Type	Number										
Application Number:	09739089										
CORRESPONDENCE DATA											
Fax Number: (703)816-4100 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>											
Phone: 703-816-4000											
Email: tlm@nixonvan.com											

Correspondent Name: Leonidas Boutsikaris/Nixon & Vanderhye	
Address Line 1: 901 N. Glebe Road	
Address Line 2: 11th Floor	
Address Line 4: Arlington, VIRGINIA 22203	
ATTORNEY DOCKET NUMBER:	LB-5424-2
NAME OF SUBMITTER:	Leonidas Boutsikaris
Signature:	/Leonidas Boutsikaris/
Date:	11/10/2009
Total Attachments: 11 source=54240002Assignment#page1.tif source=54240002Assignment#page2.tif source=54240002Assignment#page3.tif source=54240002Assignment#page4.tif source=54240002Assignment#page5.tif source=54240002Assignment#page6.tif source=54240002Assignment#page7.tif source=54240002Assignment#page8.tif source=54240002Assignment#page9.tif source=54240002Assignment#page10.tif source=54240002Assignment#page11.tif	
RECEIPT INFORMATION	
EPAS ID: PAT1030925	
Receipt Date: 11/10/2009	
Fee Amount: \$40	

[Return to home page](#)

[| .HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT								
NATURE OF CONVEYANCE:	ASSIGNMENT								
CONVEYING PARTY DATA									
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Constantinos BALAS</td><td>08/14/2002</td></tr><tr><td>Demetrios PELECOUDAS</td><td>08/14/2002</td></tr><tr><td>The Foundation of Research and Technology Hellas</td><td>08/14/2002</td></tr></tbody></table>	Name	Execution Date	Constantinos BALAS	08/14/2002	Demetrios PELECOUDAS	08/14/2002	The Foundation of Research and Technology Hellas	08/14/2002	
Name	Execution Date								
Constantinos BALAS	08/14/2002								
Demetrios PELECOUDAS	08/14/2002								
The Foundation of Research and Technology Hellas	08/14/2002								
RECEIVING PARTY DATA									
Name:	FORTH PHOTONICS LIMITED								
Street Address:	1 Mitchell Lane								
City:	Bristol								
State/Country:	UNITED KINGDOM								
Postal Code:	BS1 6BU								
PROPERTY NUMBERS Total: 1									
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>09739089</td></tr></tbody></table>	Property Type	Number	Application Number:	09739089					
Property Type	Number								
Application Number:	09739089								
CORRESPONDENCE DATA									
Fax Number:	(703)816-4100								
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>									
Phone:	703-816-4000								
Email:	tlm@nixonvan.com								
Correspondent Name:	Leonidas Boutsikaris/Nixon & Vanderhye								
Address Line 1:	901 N. Glebe Road								
Address Line 2:	11th Floor								
Address Line 4:	Arlington, VIRGINIA 22203								
ATTORNEY DOCKET NUMBER:	LB-5424-2								

NAME OF SUBMITTER:	Leonidas Boutsikaris
Signature:	/Leonidas Boutsikaris/
Date:	11/10/2009
Total Attachments: 11 source=54240002Assignment#page1.tif source=54240002Assignment#page2.tif source=54240002Assignment#page3.tif source=54240002Assignment#page4.tif source=54240002Assignment#page5.tif source=54240002Assignment#page6.tif source=54240002Assignment#page7.tif source=54240002Assignment#page8.tif source=54240002Assignment#page9.tif source=54240002Assignment#page10.tif source=54240002Assignment#page11.tif	
RECEIPT INFORMATION EPAS ID: PAT1030925 Receipt Date: 11/10/2009 Fee Amount: \$40	

DATED 14 August 2002

Intellectual Property Assignment

The Foundation of Research and Technology Hellas	(1)
Dr. Costas Balas	(2)
Dimitrios Pelecoudas	(3)
Forth Photonics Limited	(4)

S J Berwin
222 Gray's Inn Road
London WC1X 8XF
T +44 (0)20 7533 2222
F +44 (0)20 7533 2000
E info@sjberwin.com
www.sjberwin.com
DX 255 London



DATE 14 August 2002

PARTIES

- (1) The Foundation of Research and Technology Hellas of PO Box 152771110, Heraklion, Crete, Greece ("the Foundation");
- (2) Dr. Costas Balas of 12 Zacharioudakis Street, GR-71305 Heraklion, Crete, Greece;
- (3) Dimitrios Pelecoudas of 5 Kerinias Street, GR-26441 Patra, Greece, (together, "the Assignors"); and
- (4) Forth Photonics Limited (no 4446534) 1 Mitchell Lane, Bristol, England BS1 6BU ("the Assignee").

INTRODUCTION

- (A) Together, the Assignors are the proprietors of all Intellectual Property Rights in the Materials.
- (B) It is a condition of a proposed investment of up to €2,500,000 by the Investor in the Assignee that each Assignors assigns all Intellectual Property Rights held by him in the Materials to the Assignee.
- (C) Each of the Assignors have agreed to assign all Intellectual Property Rights held by him in the Materials to the Assignee on the terms and conditions set out below.
- (D) Dr. Costas Balas has also agreed to assign all Intellectual Property Rights in the Assigned Materials to the Assignee subject to the re-assignment back to him of such rights on the terms and conditions set out below.

OPERATIVE PROVISIONS

1 Interpretation

- 1.1 In this Agreement, including the Introduction and the Schedules, the words and expressions set out below, unless the context otherwise requires, have the following meanings:

Affiliate	in respect of each party, any company which at the relevant time is the ultimate holding company of that party or a subsidiary (whether direct or indirect) of that party's ultimate holding company (as those terms are defined under sections 736 and 736A of the Companies Act 1985 (as amended));
Assigned Materials	those Materials details of which are set out in Schedule 2;
Assignment Date	the date of this Agreement;
Disclosure Letter	the disclosure letter delivered by the Company, Dr. Costas Balas and the Foundation to the Investor in accordance with the terms of the Subscription Agreement;
Intellectual Property Rights	any current intellectual property rights, and any similar or analogous intangible rights and privileges, including: <ol style="list-style-type: none">(a) copyrights, trade marks, trade names, domain names, business names, rights in logos and get-



up, inventions, rights in confidential information, trade secrets and know-how including commercial know-how, design rights, patents, utility models, topographies, all rights of whatsoever nature in computer software and data, rights in databases, privacy rights; and

- (b) any rights and privileges related to any of the above;

in every case in any part of the world and whether or not registered, including in relation to the above:

- (c) all granted registrations and all applications for registration;
- (d) all renewals, reversions or extensions;
- (e) the right to sue for damages for past infringement; and
- (f) all forms of protection of a similar nature which may subsist anywhere in the world, save for, to the extent that they are not transferable under applicable law, any moral rights in connection to such Intellectual Property that exist under applicable law;

Investor	NBG Technology L.P. whose registered office is at Old Change House 128 Queen Victoria Street London EC4V 4HR;
Materials	all materials owned by (or partially owned by) or used by the Assignors and/or their employees in their business including all products and services supplied and/or developed by the Assignors, material details of which are set out in Schedule 1;
Re-assignment	the re-assignment of the Intellectual Property Rights in the Assigned Materials in accordance with the provisions of clause 3.2; and
Subscription Agreement	the subscription and shareholders' agreement dated 2002 between, among others, the Investor and the Assignee.

1.2 All definitions in clause 1.1, where the context requires, will apply:

- (a) to all references to cognate forms and plural and singular forms, and any other forms, of the words defined; and
- (b) in relation to any variations made to this Agreement.

1.3 Headings in this Agreement are for ease of reference only and do not affect the construction of any of its provisions.

1.4 In this Agreement a reference to:



- (a) persons includes a reference to any bodies corporate, unincorporated associations or partnerships;
- (b) a person includes a reference to that person's legal personal representatives, successors and permitted assigns; and
- (c) a clause or Schedule, unless the context otherwise requires, is a reference to a clause of, or Schedule to, this Agreement; and
- (d) any act or regulation, will be construed as referring also to any amendment or re-enactment (whether before or after the date of this Agreement).

2 Assignment

In consideration of the Assignee paying to each of the Assignors £1.00 (receipt of which is acknowledged by the Assignors) each of the Assignors assigns with full title guarantee to the Assignee absolutely all right, title and interest in and to all Intellectual Property Rights in the Materials, with effect from the Assignment Date provided that in respect of Materials partially owned by any of the Assignors, this assignment shall be read and construed as meaning an assignment of Intellectual Property Rights of the part owned by the relevant Assignor.

3 Re-assignment - Use

3.1 In the event that the Assignee goes into liquidation at any time, all right, title and interest in and to all Intellectual Property Rights in the Assigned Materials shall, to the extent permissible under the laws of the relevant jurisdiction, be deemed to have been automatically re-assigned to Dr. Costas Balas. In consideration for such re-assignment, Dr. Costas Balas shall pay to the Assignee the amount of £1.00. To the extent that such re-assignment is not permitted under the laws of the relevant jurisdiction, the Assignee shall take any necessary action as is permissible under the laws of the relevant jurisdiction in order to effect the re-assignment of all Intellectual Property Rights in the Assigned Materials back to Dr. Costas Balas at the price of £1.00. In the event that such re-assignment is not permitted and/or is not feasible under the laws of the relevant jurisdiction, then the Assignee shall provide to Dr. Costas Balas, to the extent permitted and feasible under the laws of the relevant jurisdiction, the right of first refusal to acquire all right, title and interest in and to all Intellectual Property Rights in the Assigned Materials.

3.2 In the event that:

- (a) the Investor does not subscribe for further shares in accordance with the Subscription Agreement; or
- (b) the Assignee, with the explicit consent of the preferred A shareholders of the Assignee, decides not to commercially exploit or develop any of the Intellectual Property Rights in the Assigned Materials or has not commercially exploited or developed any of the Intellectual Property Rights in the Assigned Materials within 24 months from the execution of this Agreement,

the Assignee shall re-assign with full title guarantee to Dr. Costas Balas absolutely all right, title and interest in and to all Intellectual Property Rights in the Assigned Materials at the price of £1.00. The Assignee covenants with Dr. Costas Balas that it will, at the direction of Dr. Costas Balas and cost of Dr. Costas Balas, do all such further acts and execute all such documents as may from time to time be necessary to vest all Intellectual Property Rights in the Assigned Materials to Dr. Costas Balas and irrevocably appoints Dr. Costas Balas as its attorney to do all such further acts and execute such documents.

- 3.3 (a) Dr. Costas Balas agrees that for a period of 5 years from the Re-assignment he shall not directly or indirectly use, or permit the use by any third party of any of the Intellectual

Property Rights in the Assigned Materials in a manner that competes with the products of the Assignor which are created or derived from the exploitation or development of the Intellectual Property Rights in the Materials (other than the Assigned Materials) from time to time.

- (b) Dr. Costas Balas agrees to comply with all reasonable instructions of the Assignor in relation to the Re-assignment and shall not disclose any of the Intellectual Property in the Assigned Materials to any third party without the prior written consent of the Assignor, save where such information is in the public domain other than through no fault of his own.
- (c) Dr. Costas Balas shall comply with all applicable laws and regulations in relation to his use of the Intellectual Property Rights in the Assigned Materials and shall not infringe the rights of any third party.
- (d) Dr. Costas Balas will pay to:
 - (i) the Assignee, for a period of six years from the date of the Re-assignment and for so long as the Assignee is not in liquidation; and
 - (ii) the Foundation, in the event that the Assignee has gone into liquidation, from the date of such liquidation until the date which is six years from the date of the Re-assignment,

the following amounts:

- (1) in the case of the Assignee, 10% of all net income received by Dr. Costas Balas throughout the world through the commercial exploitation of such Intellectual Property Rights; and
- (2) in the case of the Foundation, 5% of all net income received by Dr. Costas Balas throughout the world through the commercial exploitation of such Intellectual Property Rights.

Such amounts payable under paragraphs (1) and (2) above shall be calculated by Dr. Costas Balas (who shall keep up to date and detailed records of how the royalties were calculated) and paid to the Assignee and the Foundation on a six monthly basis in arrears within 30 days of the end of the six month period to which they relate. Both the Assignee and the Foundation shall have the right to inspect the records of Dr. Costas Balas on reasonable notice. Any underpayments revealed by such inspections shall be paid by Dr. Costas Balas plus annual interest at 4% above Barclays Bank plc's base rate from time to time. In addition, Dr. Costas Balas shall pay for the costs of any inspection where the amounts paid to the Assignee or the Foundation, as the case may be, are incorrect by 5% or more.

- (e) Dr. Costas Balas shall indemnify the Assignee against all losses, claims, liability, costs, damages, fines or expenses (including all legal costs) incurred or suffered by the Assignee or the Assignee's Affiliates arising out of or in connection with a breach of his obligations set out in this clause 3.
- (f) Following the Re-assignment, Dr. Costas Balas agrees that, for so long as he is a director or employee of the Assignee, he shall only have the right to licence the Intellectual Property Rights in Assigned Materials to any third party. Upon termination of his directorship and/or employment for any reason, Dr. Costas Balas shall be entitled to make use of such Intellectual Property Rights in Assigned Materials without restriction, subject only to the provisions of clause 3.3(a)-(e).



4 Warranty

4.1 Subject to clause 4.2, each of the Assignors warrants that:

- (a) it holds full right, title and interest in and to all Intellectual Property Rights; and
- (b) no third party has infringed or is infringing any Intellectual Property Rights in the Materials assigned under this Agreement, other than what it has been fully and fairly disclosed to the Assignee in the Disclosure Letter.

4.2 The warranty contained in clause 4.1(b) shall be subject to the limitations on liability contained in clause 13 of the Subscription Agreement and, in the case of Dimitrios Pelecoudas, the total amount of his liability for damages for breach of the warranty contained in clause 4.1(b) shall be limited to €5,000.

5 Indemnity

5.1 Each Assignor will indemnify and hold the Assignee harmless from and against all losses, claims, liability, costs, damages, fines or expenses (including all legal costs) incurred or suffered by the Assignee or the Assignee's Affiliates arising out of or in connection with breach of any of the warranties in clause 4, including without limitation any claim that the Materials infringe any third party Intellectual Property Rights ("Third Party Claim") but subject to the caps on liability for breach of warranties contained in clause 13 of the Subscription Agreement.

5.2 The Assignee will, at its absolute discretion, have the right to defend any Third Party Claim, or require the Assignors to conduct the defence of the Third Party Claim.

5.3 If the Assignee requires the Assignors to conduct the defence of a Third Party Claim, the Assignors will:

- (a) keep the Assignee fully informed of the details of the conduct of the defence;
- (b) comply with all of the Assignee's reasonable demands in relation to the conduct of the defence; and
- (c) not settle the Third Party Claim without the agreement of the Assignee, which may be granted or withheld in the Assignee's absolute discretion.

5.4 Each of the Assignors shall be jointly and severally liable for the obligations of the Assignors under this Agreement and for the warranties given by the Assignors under clause 4 of this Agreement.

5.5 In the event of any ambiguity or conflict between the terms of this clause 5 and the Subscription Agreement, the terms of the Subscription Agreement shall prevail.

6 Moral Rights

Each Assignor waives, and has procured waivers from all of its employees and subcontractors in relation to, all moral rights in respect of all of the Intellectual Property Rights owned and/or assigned to the Assignee under this Agreement arising under the Copyright, Designs and Patents Act 1988 or any other similar or analogous rights throughout the world, to the fullest extent permissible by applicable law.

7 Further Assurance

Each Assignor covenants with the Assignee that it will, at the direction of the Assignee and cost of the Assignee, do all such further acts and execute all such documents as may from time to time be necessary to vest all Intellectual Property Rights assigned to the Assignee in clause 2 in the Assignee, and irrevocably appoints the Assignee as its attorney to do all such further acts and execute such documents.

8 Non-Waiver

- 8.1 Any failure or delay in enforcing an obligation or exercising a right, under this Agreement, does not amount to a waiver of that obligation or right.
- 8.2 The waiver of a breach of a term of this Agreement does not amount to a waiver of any other term.
- 8.3 A waiver of a breach of any of the terms of this Agreement will not prevent a party from subsequently requiring compliance with the waived obligation.

9 Entire Agreement

- 9.1 This Agreement constitutes the whole agreement and understanding between the parties with respect to the subject matter of this Agreement and supersedes all prior agreements, negotiations and discussions between the parties relating to the subject matter of this Agreement.
- 9.2 The Assignee acknowledges that it has not entered into this Agreement in reliance on any statement or representation, whether or not made by an Assignor, except in so far as the representation has been incorporated into this Agreement.
- 9.3 The Assignee irrevocably and unconditionally waives any right it may have to claim damages and/or to rescind this Agreement by reason of any misrepresentation (other than a fraudulent misrepresentation) not contained in this Agreement.

10 Governing Law and Jurisdiction

This Agreement will be governed by the laws of England and Wales and the parties submit to the exclusive jurisdiction of the English Court.

11 Law of Property (Miscellaneous Provisions) Act 1994 (the "Act")

All references to "full title guarantee" in this agreement shall have the same meaning as set out in the Law of Property (Miscellaneous Provisions) Act 1994 (the "LPMPA"), save that:

- (a) the word "reasonably" shall be deleted from the covenant set out in section 2(1)(b) of the LPMPA;
- (b) the covenant set out in section 3(1) LPMPA shall not be qualified by the words "other than any charges, encumbrances or rights which that person does not and could not reasonably be expected to know about"; and
- (c) section 6(2) of the LPMPA shall not apply to any of the covenants (express or implied) deemed to be given in respect of such dispositions.



SCHEDULE 1

MATERIALS

- (1) In-vivo diagnostic methods, devices and systems based on quantitative assessment and imaging of the tissue optical response to externally administrated agent(s) which have the property to alter the pH of the tissue;
- (2) Spectral imaging methods and technologies for the non-destructive analysis and documentation of monuments and objects of artistic and historic value; and
- (3) Image analysis workstation for quantitative assessment of drusen area in retina (software copyright).


(including patents: GR 20000100102, PCT/01/00017, US 09/739089, PCT/GR00/00039 and GR 970100395).

The above materials are patents, pending patents, ideas, prototypes, products, know-how and all other elements of intellectual property as set out in the definition of Intellectual Property Rights in clause 1.1 of this Agreement. The following products also fall within the definition of Intellectual Property Rights in clause 1.1:

- (1) Diagnostic imaging device (colposcope);
- (2) Portable version of colposcope;
- (3) Self test kit for cervical pre-cancer detection;
- (4) Hyper spectral infrared camera;
- (5) Hyper Spectral CCD Camera;
- (6) High end Camera Artworks; and
- (7) Low end portable camera Artworks.

Spectral imaging methods and technologies, defined as special camera systems capable of acquiring a plurality of different narrow band spectral images and/or a spectrum per image pixel with the aid of opto-mechanical filters tailored for the following applications:

- (1) Light microscopy;
- (2) Fundus camera (ophthalmology);
- (3) Skin pathology;
- (4) Endoscopy;
- (5) Forensic;
- (6) Military;
- (7) Surveillance; and
- (8) Plant pathology.



SCHEDULE 2

ASSIGNED MATERIALS

Spectral imaging methods and technologies, defined as special camera systems capable of acquiring a plurality of different narrow band spectral images and/or a spectrum per image pixel with the aid of opto-mechanical filters tailored for the following applications:

- (1) Light microscopy;
- (2) Fundus camera (ophthalmology);
- (3) Skin pathology;
- (4) Endoscopy;
- (5) Forensic;
- (6) Military;
- (7) Surveillance; and
- (8) Plant pathology.

Two handwritten signatures are present below the list. The first signature on the left is a stylized, cursive 'G'. The second signature on the right is a more complex, cursive signature that appears to be 'JMC'.

ATTESTATION

SIGNED by *E.N. Economou*)
for and on behalf of)
THE FOUNDATION OF RESEARCH)
AND TECHNOLOGY HELLAS)
in the presence of: *Robert Roman*)

E. Economou
R. Roman

SIGNED by)
DR. COSTAS BALAS)
in the presence of:)

SIGNED by)
DIMITRIOS PELECOUDAS)
In the presence of)
Robert Roman

[Signature]
R. Roman


SIGNED by)
for and on behalf of)
FORTH PHOTONICS LIMITED)
in the presence of:)

ATTESTATION

SIGNED by)
for and on behalf of)
THE FOUNDATION OF RESEARCH)
AND TECHNOLOGY HELLAS)
in the presence of:)

SIGNED by)
DR. COSTAS BALAS)
in the presence of: Panagiotis A.)
Loukakos)






SIGNED by)
DIMITRIOS PELECOUDAS)
In the presence of Panagiotis)
A. Loukakos)



As attorney for



SIGNED by)
for and on behalf of)
FORTH PHOTONICS LIMITED)
in the presence of: Panagiotis A.)
Loukakos)



